Back to Search Start Over

Sorafenib a cost-effective option in renal cancer.

Source :
PharmacoEconomics & Outcomes News. 11/18/2006, Issue 516, p1-1. 1/4p.
Publication Year :
2006

Abstract

The article reports on the cost-effectiveness of sorafenib as drug for the treatment of advanced renal cancer, according to a Spanish study presented at the 9th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research. The mathematical model used to analyze the cost-effectiveness of the drug is presented.

Subjects

Subjects :
*RENAL cancer
*CANCER treatment
*DRUGS
*THERAPEUTICS
*COST effectiveness
*COST analysis

Details

Language :
English
ISSN :
11735503
Issue :
516
Database :
Academic Search Index
Journal :
PharmacoEconomics & Outcomes News
Publication Type :
Periodical
Accession number :
23508282
Full Text :
https://doi.org/10.2165/00151234-200605160-00001
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details